9 research outputs found
Liposomal sunitinib for ocular drug delivery : A potential treatment for choroidal neovascularization
Choroidal neovascularization (CNV) is a prevalent vision-threatening vascular disorder in aging population. CNV is associated with several diseases in the posterior segment of the eye such as age-related macular degeneration (AMD). In this study we developed sunitinib-loaded liposomes to block the neovascularization signalling pathway through inhibition of tyrosine kinase of vascular endothelial growth factor receptors (VEGFRs). Liposomal sunitinib formulations were prepared by thin film hydration method and studied for their encapsulation efficiency (EE), loading capacity (LC) and drug release profile in buffer andvitreous. Our finding showed that the liposomes (mean size 104 nm) could effectively entrap sunitinib (EE approximate to 95%) at relatively high loading capacity (LC approximate to 5%) and release sunitinib over at least 3 days. Intravitreal sunitinib-loaded liposomes revealed inhibitory effect on established neovascularization in laser-induced CNV mouse model while the intravitreal injection of sunitinib solubilized with cyclodextrin was inefficient in management of neovascularization. Accordingly, liposomal sunitinib is a promising drug delivery system that should be further studied to inhibit the CNV related to AMD.Peer reviewe
Inhibition of VCP preserves retinal structure and function in autosomal dominant retinal degeneration
Due to continuously high production rates of rhodopsin (RHO) and high metabolic activity, photoreceptor neurons are especially vulnerable to defects in proteostasis. A proline to histidine substitution at position 23 (P23H) leads to production of structurally misfolded RHO, causing the most common form of autosomal dominant Retinitis Pigmentosa (adRP) in North America. The AAA-ATPase valosin-containing protein (VCP) extracts misfolded proteins from the ER membrane for cytosolic degradation. Here, we provide the first evidence that inhibition of VCP activity rescues degenerating P23H rod cells and improves their functional properties in P23H transgenic rat and P23H knock-in mouse retinae, both in vitro and in vivo. This improvement correlates with the restoration of the physiological RHO localization to rod outer segments (OS) and properly-assembled OS disks. As a single intravitreal injection suffices to deliver a long-lasting benefit in vivo, we suggest VCP inhibition as a potential therapeutic strategy for adRP patients carrying mutations in the RHO gene
Pneumococcal Serotypes Causing Acute Otitis Media Among Children in Barcelona (1992–2011): Emergence of the Multiresistant Clone ST320 of Serotype 19A
Background: There is scarce information about changes in serotypes
and clonal types of Streptococcus pneumoniae causing acute otitis media
(AOM) in recent years, particularly in European countries.
Methods: Pneumococcal serotypes and clones from S. pneumoniae strains
isolated from children with AOM who were attended at Hospital Sant Joan
de Déu, Barcelona (1992 to 2011), were studied. Heptavalent pneumococ-
cal conjugate vaccine (PCV7) was introduced in June 2001. We defined 3
periods: prevaccine period 1992 to 2001, early vaccine period 2002 to 2006
and late vaccine period 2007 to 2011.
Results: There were 376 pneumococcal strains causing AOM, and 373
(99.2%) of them were serotyped. AOM caused by PCV7 serotypes declined
significantly: 161 of 245 (65.7%) episodes in 1992 to 2001 versus 22 of
67 (32.8%) in 2002 to 2006 versus 8 of 61 (13.1%) in 2007 to 2011 P <
0.001. In the last period (2007 to 2011), the potential serotype coverage for
the PCV10 was 16.4% and for the PCV13 was 68.9% (P < 0.001). Sero-
type 19A increased from 5.7% in 1992 to 2001 to 42.6% in 2007 to 2011
(P < 0.001). Among strains with penicillin minimal inhibitory concentra-
tion ≥0.12 μg/mL (n = 241), serotype 19A rose from 2.3% in the first period
to 57.9 % in the last period (P < 0.001). The clonal-type ST320 was initially
detected in 2005, and in the period 2007 to 2011, the ST320 was found in
72.7% of nonsusceptible serotype 19A isolates.
Conclusions: Among children with AOM, a rapid expansion of the mul-
tiresistant clone ST320 expressing serotype 19A has been observed in Bar-
celona. The implementation of PCV13, which includes this serotype, may
decrease the prevalence of AOM and reduce antimicrobial resistance
High invasiveness of pneumococcal serotypes included in the new generation of conjugate vaccines
The implementation of the seven-valent pneumococcal conjugate vaccine, PCV7, has resulted in significant changes in the pneumococcal
population being carried and causing disease. We aimed to determine the invasive disease potential of serotypes causing invasive paediatric
disease in the era of conjugate vaccines in Catalonia, Spain, and their potential coverage by the 13-valent pneumococcal conjugate vaccine,
PCV13. As a secondary objective, we evaluated whether implementation of PCV7 had resulted in significant changes in the invasive disease
potential of the most frequent serotypes circulating in the area. Two pneumococcal collections obtained from children admitted to the
University Hospital Sant Joan de Deu (Barcelona, Spain) between 2007 and 2011 were compared: a first set of 159 invasive disease isolates,
and a second set of 209 nasopharyngeal isolates recovered from healthy children admitted for minor surgery. The most common invasive
serotypes were 1 (24.5%, n = 39), 19A (21.2%, n = 34), 5 (8.8%, n = 14), 7F (8.8%, n = 14) and 3 (5%, n = 8). The most common serotypes
in carriage were 19A (10%, n = 21), 6C (9%, n = 19), 23B (8.1%, n = 17), 6A (7.6%, n = 16) and 19F (6.2%, n = 13). A significantly higher
propensity to cause invasive disease was observed for serotypes 1, 3, 5, 7F and 19A, all of which are included in PCV13. After
false-discovery-rate correction, the results were robust for serotypes 1, 5, 7F and 19A. Non-PCV13 serotypes had a low invasive disease
potential. Our data reinforce the need for continuous surveillance and should encourage efforts to introduce universal vaccination with
PCV13 in children in our region
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach
Outcomes of people living with HIV (PLWH) developing non-AIDS events (NAEs) remain poorly defined. We aimed to classify NAEs according to severity, and to describe clinical outcomes and prognostic factors after NAE occurrence using data from CoRIS, a large Spanish HIV cohort from 2004 to 2013. Prospective multicenter cohort study. Using a multistate approach we estimated 3 transition probabilities: from alive and NAE-free to alive and NAE-experienced ("NAE development"); from alive and NAE-experienced to death ("Death after NAE"); and from alive and NAE-free to death ("Death without NAE"). We analyzed the effect of different covariates, including demographic, immunologic and virologic data, on death or NAE development, based on estimates of hazard ratios (HR). We focused on the transition "Death after NAE". 8,789 PLWH were followed-up until death, cohort censoring or loss to follow-up. 792 first incident NAEs occurred in 9.01% PLWH (incidence rate 28.76; 95% confidence interval [CI], 26.80-30.84, per 1000 patient-years). 112 (14.14%) NAE-experienced PLWH and 240 (2.73%) NAE-free PLWH died. Adjusted HR for the transition "Death after NAE" was 12.1 (95%CI, 4.90-29.89). There was a graded increase in the adjusted HRs for mortality according to NAE severity category: HR (95%CI), 4.02 (2.45-6.57) for intermediate-severity; and 9.85 (5.45-17.81) for serious NAEs compared to low-severity NAEs. Male sex (HR 2.04; 95% CI, 1.11-3.84), ag
Recommended from our members
More than one million barriers fragment Europe’s rivers
Rivers support some of Earth’s richest biodiversity and provide essential ecosystem services to society, but they are often fragmented by barriers to free flow. In Europe, attempts to quantify river connectivity have been hampered by the absence of a harmonized barrier database. Here we show that there are at least 1.2 million instream barriers in 36 European countries (with a mean density of 0.74 barriers per kilometre), 68 per cent of which are structures less than two metres in height that are often overlooked. Standardized walkover surveys along 2,715 kilometres of stream length for 147 rivers indicate that existing records underestimate barrier numbers by about 61 per cent. The highest barrier densities occur in the heavily modified rivers of central Europe and the lowest barrier densities occur in the most remote, sparsely populated alpine areas. Across Europe, the main predictors of barrier density are agricultural pressure, density of river-road crossings, extent of surface water and elevation. Relatively unfragmented rivers are still found in the Balkans, the Baltic states and parts of Scandinavia and southern Europe, but these require urgent protection from proposed dam developments. Our findings could inform the implementation of the EU Biodiversity Strategy, which aims to reconnect 25,000 kilometres of Europe’s rivers by 2030, but achieving this will require a paradigm shift in river restoration that recognizes the widespread impacts caused by small barriers